NBD AI Bulletin -- Hubei Biocause Pharmaceutical Co., Ltd. (the Company, SZ 000627, closing price: 5.1 yuan) announced on November 18 that the Company recently received a notification from its controlling shareholder Xinliyi Group Co., Ltd.
The notification said that Xinliyi Group Co., Ltd. pledged about 204.5 million shares on November 17, 2020, accounting for 9.82% of its holdings. As of November 17, 2020, Xinliyi Group Co., Ltd. holds about 2.082 billion shares and has pledged a total of about 1.144 billion shares.
The cumulative number of pledged shares due in the next year is about 940 million, accounting for 45.14% of its holdings and 19.02% of the Company's total share capital. The margin balance is 3.38 billion yuan and the source of repayment is bond investment. Xinliyi Group Co., Ltd. has a strong capacity to pay off its debt.
According to the 2019 semi-annual report, Hubei Biocause Pharmaceutical Co., Ltd. mainly engages in insurance and pharmaceutical businesses, accounting for 98.89% and 1.1% of revenue, respectively.
Hubei Biocause Pharmaceutical Co., Ltd.'s chairman is Liu Yiqian, male, 57, Chinese national, no permanent residence abroad, secondary school education. Hubei Biocause Pharmaceutical Co., Ltd.'s general manager is Zhou Wenxia, female, 48 years old, Chinese national, no permanent residence abroad, with a master's degree.
Tips on "Stock Trends":
1. The number of shares held by northbound investors increased by 3.6352 million in the past 30 days, representing 0.09% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
(By Tan Yuhan)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.